content: <PAGE>
  
                         SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
  
                                      FORM 8-K
  
                  Current Report Pursuant to Section 13 or 15(d) of
                         The Securities Exchange Act of 1934
  
  
  
         Date of Report (Date of earliest event reported) February 26, 2002
  
  
                          Fusion Medical Technologies, Inc.
  --------------------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
  
           Delaware                      000-28460                94-3177221
  ----------------------------- ---------------------------- ---------------------
  (State or Other Jurisdiction         (Commission              (IRS Employer
       of Incorporation)                File Number)           Identification No.)
  
                              34715 Ardenwood Boulevard
                              Fremont, California 94555
  --------------------------------------------------------------------------------
                 (Address of Principal Executive Offices) (Zip Code)
  
  Registrant's telephone number, including area code:  (510) 818-4600
                                                       ---------------------------
  
                                   Not Applicable
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  
  
  
  <PAGE>
  
  ITEM 5.  Other Events
  
  On February 27, 2002, Fusion Medical Technologies, Inc., a Delaware corporation
  ("Fusion"), and Baxter International Inc., a Delaware corporation ("Baxter")
  issued a joint press release announcing the execution of an Agreement and Plan
  of Merger and Reorganization, dated as of February 26, 2002 (the "Merger
  Agreement"), by and among Baxter, HB2002 Corporation, a Delaware corporation and
  a wholly-owned subsidiary of Baxter ("Merger Sub"), and Fusion. In accordance
  with the Merger Agreement, Merger Sub will be merged with and into Fusion with
  Fusion continuing as the surviving corporation and a wholly-owned subsidiary of
  Baxter (the "Merger"). As a result of the Merger, each issued and outstanding
  share of Fusion Common Stock, par value $0.001 per share, will be automatically
  converted into the right to receive the fraction of a share of Baxter Common
  Stock, par value $1.00 per share ("Baxter Share"), equal to $10.00 divided by
  the average closing sale price of one Baxter Share for the ten consecutive
  trading days ending on and including the third trading day prior to the date of
  the meeting of Fusion's stockholders to approve the Merger. In connection with
  the Merger Agreement, all of the directors and executive officers and certain
  other principal stockholders of Fusion holding an aggregate of approximately
  3,255,916 shares of Fusion Common Stock, or approximately 22% of the outstanding
  shares, and options to acquire 1,499,918 shares of Fusion Common Stock, have
  entered into voting agreements with Baxter, dated February 26, 2002 and have
  delivered irrevocable proxies (the "Proxies") to Baxter, pursuant to which they
  have agreed to vote their Fusion shares in favor of the adoption and approval of
  the Merger Agreement and approval of the Merger, in favor of the other actions
  contemplated by the Merger Agreement, against the approval of any offer or
  proposal regarding a merger, sale, tender offer, or other similar transaction
  involving Fusion, against any proposal made in opposition to, or in competition
  with, the Merger and the transactions contemplated by the Merger Agreement, and
  against any other action that is intended to, or could reasonably be expected to
  impede, interfere with, delay, postpone, discourage or adversely affect the
  Merger. The consummation of the Merger is subject to the approval of the
  stockholders of Fusion, receipt of necessary approvals under applicable
  antitrust laws, SEC clearance and other customary closing conditions. The Merger
  is intended to qualify as a tax-free reorganization under Section 368 of the
  Internal Revenue Code of 1986, as amended.
  
  
           A copy of the Merger Agreement is filed as Exhibit 2.1 hereto and is
  incorporated herein by reference. A copy of the form of Voting Agreement is
  filed as Exhibit 2.2 and is incorporated herein by reference. A copy of the
  joint press release is filed as Exhibit 99.1 hereto and is incorporated herein
  by reference.
  
  ITEM 7.  Financial Statements and Exhibits
  
  Exhibit No.    Description
  -----------    -----------
  
  2.1            Agreement and Plan of Merger and Reorganization, dated as of
                 February 26, 2002, by and among Baxter International Inc., HB2002
                 Corporation and Fusion Medical Technologies, Inc.
  
  2.2            Form of Voting Agreement, dated as of February 26, 2002, by and
                 among Baxter International Inc., HB2002 Corporation and certain
                 stockholders of Fusion Medical Technologies, Inc.
  
  99.1           Text of Joint Press Release of Fusion Medical Technologies, Inc.
                 and Baxter International Inc., dated February 27, 2002.
  
                                        -2-
  
  <PAGE>
  
                                      SIGNATURE
  
           Pursuant to the requirements of the Securities Exchange Act of 1934, as
  amended, the registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunto duly authorized.
  
                                            FUSION MEDICAL TECHNOLOGIES, INC.
  
                                            By:  /s/ Larry Strauss
                                                 -----------------
                                                 Larry Strauss
  
                                                 Vice President, Finance and Chief
                                                 Financial Officer
  
  Dated:  March 1, 2002
  
                                        -3-
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.txt", "description": "FORM 8-K", "secsgml_size_bytes": 5963}]
metadata_filer: {"company-data": {"conformed-name": "FUSION MEDICAL TECHNOLOGIES INC", "cik": "0001013466", "assigned-sic": "3841", "irs-number": "943177221", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28460", "film-number": "02564975"}, "business-address": {"street1": "1615 PLYMOUTH STREET", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043", "phone": "4159034000"}, "mail-address": {"street1": "1615 PLYMOUTH STREET", "city": "MOUNTAIN VIEW", "state": "CA", "zip": "94043"}}
text: SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                  Current Report Pursuant to Section 13 or 15(d) of
                         The Securities Exchange Act of 1934
  
         Date of Report (Date of earliest event reported) February 26, 2002
  
                          Fusion Medical Technologies, Inc.
  --------------------------------------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                      000-28460                94-3177221
  ----------------------------- ---------------------------- ---------------------
  (State or Other Jurisdiction         (Commission              (IRS Employer
       of Incorporation)                File Number)           Identification No.)
  
                              34715 Ardenwood Boulevard
                              Fremont, California 94555
  --------------------------------------------------------------------------------
                 (Address of Principal Executive Offices) (Zip Code)
  
  Registrant's telephone number, including area code:  (510) 818-4600
                                                       ---------------------------
  
                                   Not Applicable
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  ITEM 5.  Other Events
  
  On February 27, 2002, Fusion Medical Technologies, Inc., a Delaware corporation
  ("Fusion"), and Baxter International Inc., a Delaware corporation ("Baxter")
  issued a joint press release announcing the execution of an Agreement and Plan
  of Merger and Reorganization, dated as of February 26, 2002 (the "Merger
  Agreement"), by and among Baxter, HB2002 Corporation, a Delaware corporation and
  a wholly-owned subsidiary of Baxter ("Merger Sub"), and Fusion. In accordance
  with the Merger Agreement, Merger Sub will be merged with and into Fusion with
  Fusion continuing as the surviving corporation and a wholly-owned subsidiary of
  Baxter (the "Merger"). As a result of the Merger, each issued and outstanding
  share of Fusion Common Stock, par value $0.001 per share, will be automatically
  converted into the right to receive the fraction of a share of Baxter Common
  Stock, par value $1.00 per share ("Baxter Share"), equal to $10.00 divided by
  the average closing sale price of one Baxter Share for the ten consecutive
  trading days ending on and including the third trading day prior to the date of
  the meeting of Fusion's stockholders to approve the Merger. In connection with
  the Merger Agreement, all of the directors and executive officers and certain
  other principal stockholders of Fusion holding an aggregate of approximately
  3,255,916 shares of Fusion Common Stock, or approximately 22% of the outstanding
  shares, and options to acquire 1,499,918 shares of Fusion Common Stock, have
  entered into voting agreements with Baxter, dated February 26, 2002 and have
  delivered irrevocable proxies (the "Proxies") to Baxter, pursuant to which they
  have agreed to vote their Fusion shares in favor of the adoption and approval of
  the Merger Agreement and approval of the Merger, in favor of the other actions
  contemplated by the Merger Agreement, against the approval of any offer or
  proposal regarding a merger, sale, tender offer, or other similar transaction
  involving Fusion, against any proposal made in opposition to, or in competition
  with, the Merger and the transactions contemplated by the Merger Agreement, and
  against any other action that is intended to, or could reasonably be expected to
  impede, interfere with, delay, postpone, discourage or adversely affect the
  Merger. The consummation of the Merger is subject to the approval of the
  stockholders of Fusion, receipt of necessary approvals under applicable
  antitrust laws, SEC clearance and other customary closing conditions. The Merger
  is intended to qualify as a tax-free reorganization under Section 368 of the
  Internal Revenue Code of 1986, as amended.
  
           A copy of the Merger Agreement is filed as Exhibit 2.1 hereto and is
  incorporated herein by reference. A copy of the form of Voting Agreement is
  filed as Exhibit 2.2 and is incorporated herein by reference. A copy of the
  joint press release is filed as Exhibit 99.1 hereto and is incorporated herein
  by reference.
  
  ITEM 7.  Financial Statements and Exhibits
  
  Exhibit No.    Description
  -----------    -----------
  
  2.1            Agreement and Plan of Merger and Reorganization, dated as of
                 February 26, 2002, by and among Baxter International Inc., HB2002
                 Corporation and Fusion Medical Technologies, Inc.
  
  2.2            Form of Voting Agreement, dated as of February 26, 2002, by and
                 among Baxter International Inc., HB2002 Corporation and certain
                 stockholders of Fusion Medical Technologies, Inc.
  
  99.1           Text of Joint Press Release of Fusion Medical Technologies, Inc.
                 and Baxter International Inc., dated February 27, 2002.
  
                                        -2-
  SIGNATURE
  
           Pursuant to the requirements of the Securities Exchange Act of 1934, as
  amended, the registrant has duly caused this report to be signed on its behalf
  by the undersigned hereunto duly authorized.
  
                                            FUSION MEDICAL TECHNOLOGIES, INC.
  
                                            By:  /s/ Larry Strauss
                                                 -----------------
                                                 Larry Strauss
  
                                                 Vice President, Finance and Chief
                                                 Financial Officer
  
  Dated:  March 1, 2002
  
                                        -3-